## **Core Concept**
Aspirin exerts its effects by inhibiting the enzyme cyclooxygenase (COX), which plays a crucial role in the synthesis of prostaglandins and thromboxanes from arachidonic acid. This action is fundamental in understanding aspirin's anti-inflammatory, analgesic, antipyretic, and antiplatelet properties.

## **Why the Correct Answer is Right**
At low doses, aspirin preferentially inhibits **COX-1** over COX-2. COX-1 is constitutively expressed in many tissues, including platelets, where it is involved in the production of thromboxane A2 (TXA2), a potent stimulator of platelet aggregation. By irreversibly inhibiting COX-1 in platelets, low-dose aspirin effectively reduces TXA2 production, leading to an antiplatelet effect. This is why low-dose aspirin is often used for cardiovascular protection.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because, although COX-2 is involved in inflammatory processes and is inducible at sites of inflammation, low-dose aspirin's primary effect is not on COX-2 but on COX-1.
- **Option B:** This option might seem plausible because lipoxygenase is another enzyme involved in the metabolism of arachidonic acid, leading to the production of leukotrienes. However, aspirin's primary mechanism of action at low doses is not through the inhibition of lipoxygenase.
- **Option C:** This option could potentially refer to another target or pathway but is not directly relevant to aspirin's mechanism of action at low doses.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that low-dose aspirin therapy is often used for its antiplatelet effects to prevent cardiovascular events, such as myocardial infarction and stroke, in high-risk patients. The "low dose" typically refers to 75-100 mg/day, which is sufficient to inhibit platelet aggregation without significantly affecting COX-2-mediated prostaglandin production.

## **Correct Answer:** . COX-1